Central regions | Technology & innovation

Russian company develops new leukemia drug candidate

25 Apr '14
Fusion Pharma, a biotech developer at the Skolkovo innovation hub outside Moscow, has come up with a new leukemia drug candidate and is gearing up for clinical trials, the Skolkovo Foundation website announced.

We will do our best to launch the clinical trials of the PF-114 candidate as soon as possible, the Foundation cited a statement by Germes Chilov, Ph.D. in chemistry, the CEO of Fusion Pharma.

The new drug candidate was presented last week in Moscow at the 2nd Hematologists Congress of Russia.

According to Prof. Ann Turkina, M.D., a Russian specialist in chemotherapy of myeloproliferative diseases, the coming of a new drug to treat chronic myeloleucosis is a timely development, as at the moment there are many patients resistant to currently available therapies.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content


Tags: Skolkovo (322) / leukemia (2) / PF 114 (0) / Fusion Pharma (0) /

Latest News: Central regions
17 Oct '17 | Finance, business | Technology & innovation
13 Oct '17 | Finance, business | Retail, FMCG
12 Oct '17 | Finance, business | Technology & innovation

Feature stories

7 Sep '17
26 Jul '17
Scientists at Tomsk Polytechnic (TPU) in Siberia have...
20 Jun '17
In regions most of European Russians will hardly ever...
Search (News archive - 21174)
Marchmont News

Latest News

20 Oct '17
Infectex, a Russian biomed company, is readying for...
19 Oct '17
Russian scientists in partnership with their Korean...
18 Oct '17
Scientists at the Novosibirsk-based Boreskov...

Most read stories from last week

20 Oct '17
Infectex, a Russian biomed company, is readying for...